A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity. Arbaclofen ER will be compared with placebo.

开始日期2026-01-01

申办/合作机构

RVL Pharmaceuticals, Inc.

NCT05617118 / RecruitingN/AIIT

Evaluation of Efficacy and Safety of Oral Baclofen Taking in Comparison With Botulinum Toxin A Injections in Myofascial Pelvic Pain Syndrome. Prospective Multicenter Cohort Study.

The aim of the study is to test the hypothesis that oral taking of baclofen in therapeutic dosage for 60 days is equally effective as injection of botulinum toxin type "A" in the area of trigger points of the pelvic muscles.

开始日期2022-12-01

申办/合作机构

St. Petersburg State University

[+1]

NCT04271332 / Active, not recruiting临床2期IIT

An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 Deletion

This Phase 2 study examines the safety, tolerability, and efficacy of arbaclofen in pediatric subjects with 16p11.2 deletion. Male or female subjects aged 5 to 17 years of age will be randomized to receive either placebo or arbaclofen in a double-blind study design. If the subject completes all study requirements through Visit 4 (Close-out Visit), he/she may be eligible for an optional open-label study with arbaclofen.

开始日期2022-09-01

申办/合作机构

Clinical Research Associates, LLC

100 项与 Baclofen Extended Release 相关的临床结果

登录后查看更多信息

100 项与 Baclofen Extended Release 相关的转化医学

登录后查看更多信息

100 项与 Baclofen Extended Release 相关的专利（医药）

登录后查看更多信息

129

项与 Baclofen Extended Release 相关的文献（医药）

2025-01-01·Progress in Neuro-Psychopharmacology and Biological Psychiatry

The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future

Review

作者: Mirabelli, Silvestro ; Cortese, Samuele ; Parlatini, Valeria ; Persico, Antonio M. ; Asta, Lisa ; Arango, Celso ; Chehbani, Fethia ; Vitiello, Benedetto ; Persico, Antonio M

Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the Clinicaltrials.gov website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including N-acetylcysteine, folinic acid, l-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize "drug-based" information, which will be ultimately merged to provide clinicians with a "symptom-based" consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.

2025-01-01·Neuropharmacology

Clinically-probed mechanisms of action in Fragile-X syndrome fail to normalize translational EEG phenotypes in Fmr1 knockout mice

Article

作者: Redondo, Roger L ; Bainier, Marie ; Janz, Philipp ; Gross, Simon ; Redondo, Roger L. ; Marashli, Samuel

Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by Fragile X Messenger Ribonucleoprotein (FMRP) deficiency. Electroencephalogram (EEG) changes in FXS include alterations of oscillatory activity and responses to sensory stimuli, some of which have been back-translated into rodent models by knocking-out the Fragile X messenger ribonucleoprotein 1 gene (Fmr1-KO). However, the validity of these EEG phenotypes as objective biomarkers requires further investigation. Potential pharmacotherapies such as mGluR5 inhibitors (e.g. CTEP; 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole-4-yl)ethynyl)pyridine), GABA_BR agonists (e.g. arbaclofen) and δ-containing GABA_AR agonists (e.g. gaboxadol) have not translated into clinical success despite rescuing many phenotypes in the Fmr1-KO model. Yet none of these treatments have been assessed on EEG phenotypes in the Fmr1-KO model. Therefore, we set out to discover new EEG phenotypes in Fmr1-KO mice, using "task-free" and auditory-evoked (AEPs) and visually-evoked potential (VEP) paradigms, and probe their modulation by CTEP, arbaclofen and gaboxadol, using within-subjects designs. First, we report Fmr1-KO-associated EEG abnormalities that closely resemble those observed in FXS, including elevated gamma-band power, reduced alpha/beta-band coherence, increased AEPs and delayed VEPs. Secondly, we found that pharmacological treatment, at best, only partially normalized EEG phenotypes. CTEP restored alpha/beta-band coherence and AEP amplitudes but failed to normalize gamma power and VEP latencies. Conversely, arbaclofen reduced gamma power but did not restore coherence or AEP amplitudes and further delayed VEPs. Gaboxadol did not normalize any EEG phenotypes. We conclude that these compounds have limited ability to normalize these EEG phenotypes.

2024-07-30·Journal of Alzheimer's Disease

Screening Targets and Therapeutic Drugs for Alzheimer’s Disease Based on Deep Learning Model and Molecular Docking

Article

作者: Zhong, Man-Li ; Li, Jia-Yi ; Gao, Hui-Ling ; Zhang, Ya-Hong ; Zhao, Pu

Background: Alzheimer’s disease (AD) is a neurodegenerative disorder caused by a complex interplay of various factors. However, a satisfactory cure for AD remains elusive. Pharmacological interventions based on drug targets are considered the most cost-effective therapeutic strategy. Therefore, it is paramount to search potential drug targets and drugs for AD. Objective: We aimed to provide novel targets and drugs for the treatment of AD employing transcriptomic data of AD and normal control brain tissues from a new perspective. Methods: Our study combined the use of a multi-layer perceptron (MLP) with differential expression analysis, variance assessment and molecular docking to screen targets and drugs for AD. Results: We identified the seven differentially expressed genes (DEGs) with the most significant variation (ANKRD39, CPLX1, FABP3, GABBR2, GNG3, PPM1E, and WDR49) in transcriptomic data from AD brain. A newly built MLP was used to confirm the association between the seven DEGs and AD, establishing these DEGs as potential drug targets. Drug databases and molecular docking results indicated that arbaclofen, baclofen, clozapine, arbaclofen placarbil, BML-259, BRD-K72883421, and YC-1 had high affinity for GABBR2, and FABP3 bound with oleic, palmitic, and stearic acids. Arbaclofen and YC-1 activated GABAB receptor through PI3K/AKT and PKA/CREB pathways, respectively, thereby promoting neuronal anti-apoptotic effect and inhibiting p-tau and Aβ formation. Conclusions: This study provided a new strategy for the identification of targets and drugs for the treatment of AD using deep learning. Seven therapeutic targets and ten drugs were selected by using this method, providing new insight for AD treatment.

项与 Baclofen Extended Release 相关的新闻（医药）

2023-12-11

·PRNewswire

Arbaclofen ER Emerging Drug Insight and Market Forecast to 2032

DUBLIN, Dec. 11, 2023 /PRNewswire/ -- The "Arbaclofen ER Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about Arbaclofen ER for spasticity in the seven major markets. A detailed picture of the Arbaclofen ER for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Arbaclofen ER for spasticity. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Arbaclofen ER market forecast analysis for spasticity in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in spasticity. Drug Summary Arbaclofen ER is an extended-release formulation of arbaclofen, the R isomer of baclofen that leverages the proprietary for osmodex drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis. It acts upstream of the mGluR5 receptor to increase inhibitory neurotransmission. It is the isomer of baclofen which harbors antispastic activity. The company is exploring opportunities to sell or out-license late-stage product candidate arbaclofen ER tablets designed to alleviate signs and symptoms of spasticity resulting from multiple sclerosis, for which they have completed Phase III clinical trials. The report provides insights into: A comprehensive product overview including the Arbaclofen ER description, mechanism of action, dosage and administration, research and development activities in spasticity. Elaborated details on Arbaclofen ER regulatory milestones and other development activities have been provided in this report. The report also highlights the Arbaclofen ER research and development activities in spasticity across the United States, Europe and Japan. The report also covers the patents information with expiry timeline around Arbaclofen ER. The report contains forecasted sales of Arbaclofen ER for spasticity till 2032. Comprehensive coverage of the late-stage emerging therapies for spasticity. The report also features the SWOT analysis with analyst views for Arbaclofen ER in spasticity. In-depth Arbaclofen ER Market Assessment This report provides a detailed market assessment of Arbaclofen ER for spasticity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032. Arbaclofen ER Clinical Assessment The report provides the clinical trials information of Arbaclofen ER for spasticity covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for spasticity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Arbaclofen ER dominance. Other emerging products for spasticity are expected to give tough market competition to Arbaclofen ER and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Arbaclofen ER in spasticity. This in-depth analysis of the forecasted sales data of Arbaclofen ER from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Arbaclofen ER in spasticity. Key Questions What is the product type, route of administration and mechanism of action of Arbaclofen ER? What is the clinical trial status of the study related to Arbaclofen ER in spasticity and study completion date? What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Arbaclofen ER development? What are the key designations that have been granted to Arbaclofen ER for spasticity? What is the forecasted market scenario of Arbaclofen ER for spasticity? What are the forecasted sales of Arbaclofen ER in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? What are the other emerging products available and how are these giving competition to Arbaclofen ER for spasticity? Which are the late-stage emerging therapies under development for the treatment of spasticity? Key Topics Covered: 1. Report Introduction 2. Arbaclofen ER Overview in Spasticity 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Regulatory Milestone 2.4. Other Developmental Activities 2.5. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. Arbaclofen ER Market Assessment 5.1. Market Outlook of Arbaclofen ER in Spasticity 5.2. 7MM Analysis 5.2.1. Market Size of Arbaclofen ER in the 7MM for Spasticity 5.3. Country-wise Market Analysis 6. SWOT Analysis 7. Analysts' Views For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

临床3期

2023-09-18

·PRNewswire

Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen

CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded its intellectual property rights with a new patent family. A new patent family was filed to the United States Patent Trademark & Office earlier in 2023. This new patent family comes in addition to an existing granted patent family. Continue Reading Allos also announces today the worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including Autism Spectrum Disorder. This is in addition to the current Fragile X Syndrome development program, for which there are no approved medications, and where arbaclofen has Orphan Drug Designation. Expanded arbaclofen rights with a newly filed patent family and with exclusive rights in all indications, incl. Autism. Tweet this "This license builds upon the progress in our Fragile X Syndrome program, where we have achieved alignment with the fragile X community and the FDA on the design of the confirmatory Phase 3 clinical trial. We are excited to have the rights to develop arbaclofen in additional indications as clear efficacy signals were observed in recent trials in individuals with idiopathic Autism Spectrum Disorder." said Dr. Randall Carpenter, MD, co-founder of Allos Pharma Inc. In May 2023, the results of two autism studies, in Canada (n=90) and EU (n=122), were presented at the annual meeting of the International Society for Autism Research. The two studies had nearly identical protocols and endpoints. Improvement was seen in both studies on the primary endpoint (Socialization Domain, Vineland-3) but did not reach statistical significance. Nominally significant improvements were seen in one or both studies on other measures of social skill (Social Responsiveness Scale, Aberrant Behavior Checklist-Social Withdrawal, Autism Impact Measure). A subject-level meta-analysis is planned. "We remain committed to providing new treatment options for patients and families affected by Fragile X Syndrome and Autism Spectrum Disorder, and we believe that arbaclofen has the potential to make a significant, positive impact on their lives." Dr. Randall Carpenter, MD, co-founder of Allos Pharma Inc About Allos Pharma Inc. Allos Pharma Inc. is a biopharmaceutical company dedicated to the development of treatments for rare neurological disorders. Allos' investigational drug, arbaclofen, is currently in development for the treatment of Fragile X Syndrome and Autism Spectrum Disorder. For more information, please visit Allos Pharma Inc.'s website at SOURCE Allos Pharma Inc.

临床3期孤儿药

2023-08-18

·Pharmaceutical Technology

AbbVie achieves win for migraine prevention drug Aquipta in Europe

Adam Zamecnik @a_zamecnik The approval of Aquipta is based on the results of the two Phase III studies. Credit: Shutterstock / Prostock-studio. The European Commission has approved AbbVie’s Aquipta as migraine prophylaxis for adult patients, making it the first daily oral treatment of its class to be approved in the EU for the prevention of both chronic and episodic migraines. Several calcitonin gene-related peptide (CGRP) antibodies are administered subcutaneously or via intravenous infusions. But there is a preference among patients for oral therapies, says Dawn Carlson, vice president, Neuroscience Development at AbbVie , in an interview with Pharmaceutical Technology. Lundbeck’s CGRP antibody Vyepti (eptinezumab), is administered through intravenous infusions, while Amgen’s Aimovig (erenumab) is injected subcutaneously. Recommended Reports Reports LOA and PTSR Model - Dexmedetomidine in Opium (Opioid) Addiction GlobalData Reports LOA and PTSR Model - Arbaclofen Er in Opium (Opioid) Addiction GlobalData View all Companies Intelligence AbbVie Inc Amgen Inc Lundbeck LLC Progress Kft View all The approval of Aquipta is based on the results of the two Phase III studies—ADVANCE (NCT03777059) and PROGRESS (NCT03855137), which both met their primary endpoint of a statistically significant reduction in mean monthly migraine days versus placebo, per the 17 August announcement . In the PROGRESS trial, patients in the 60mg Aquipta cohort reported a 6.8-day reduction in mean monthly migraine days, while those on placebo experienced a 5.1-day reduction. Such a reduction represents a clinically meaningful change in the experience of patients who feel pain not just during the actual migraine attack, but also in the symptoms prior to the attack, explains Carlson. The studies’ secondary endpoints were equally meaningful, with decreases in headache days and medication use, she adds. Also known as atogepant, Aquipta is a CGRP receptor antagonist (gepant). The US Food and Drug Administration (FDA) first approved the treatment for prophylactic use as an episodic migraine treatment in September 2021. In April 2023, AbbVie managed to expand the drug’s label to chronic migraines. While the drug’s European brand name is Aquipta, it is sold under the name Qulipta in Canada and the US. Carlson says: “Now that we’ve received approval, AbbVie is committed to bringing these expeditiously to patients and we’re working with the appropriate country authorities and reimbursement agencies to bring these solutions as quickly as we can…But that will take some time.” According to a GlobalData consensus sales forecast, Aquipta/Qulipta is projected to have global sales of $1.37bn in 2029. GlobalData is the parent company of Pharmaceutical Technology . Beyond the EU and countries where the drug was already approved, AbbVie is on the lookout for further expansion. “We know that migraine is a global disease with over a billion patients suffering, and we are committed to exploring options in other countries. And that’s on a case-by-case basis, but we are looking at other areas to bring this forward because AbbVie is committed to finding solutions for patients suffering from migraine.”

临床3期临床结果上市批准

100 项与 Baclofen Extended Release 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Baclofen Extended Release	-	DB08891

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脆性X综合征	临床3期	-	Allos Therapeutics, Inc.	-
多发性硬化症	临床1期	乌克兰	Osmotica Pharmaceutical US LLC	2012-11-01
多发性硬化症	临床1期	俄罗斯	Osmotica Pharmaceutical US LLC	2012-11-01
多发性硬化症	临床1期	美国	Osmotica Pharmaceutical US LLC	2012-11-01
肌肉痉挛	临床1期	俄罗斯	Osmotica Pharmaceutical US LLC	2012-11-01
自闭症谱系障碍	临床1期	美国	Seaside Therapeutics LLC	2011-11-01
多发性硬化症	临床前	美国	Osmotica Pharmaceutical US LLC	2012-11-01
多发性硬化症	临床前	乌克兰	Osmotica Pharmaceutical US LLC	2012-11-01
自闭症谱系障碍	临床前	美国	Seaside Therapeutics LLC	2011-11-01
多发性硬化症	药物发现	俄罗斯	Osmotica Pharmaceutical US LLC	2012-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03319732 (OS440-3005, CTgov)	临床3期	肌肉痉挛 \| 多发性硬化症	323	Arbaclofen	壓製壓夢糧餘糧顧鹽鹽(製艱範積構齋鹹網憲夢) = 獵廠蓋夢壓顧鑰壓積選齋鹽積壓衊獵觸蓋簾蓋 (襯顧鏇鬱壓鹽製獵膚獵, 夢鏇廠選齋積窪網鑰遞 ~ 範淵選觸顧憲鹹憲鹽範) 更多	-	2022-07-15
NCT03290131 (OS440-3004, CTgov)	临床3期	肌肉痉挛 \| 多发性硬化症	536	Arbaclofen (AERT 40 mg)	鏇蓋艱淵願構淵顧糧網(襯鏇膚淵構糧鏇憲遞艱) = 築壓觸壓獵鹽鑰餘糧遞選淵築鹹夢淵積淵鏇範 (築憲齋獵鹹淵選蓋製鹹, 製廠廠餘夢繭憲網遞簾 ~ 廠獵繭積鹽憲鑰襯衊鏇) 更多	-	2022-07-15
				Arbaclofen (AERT 80 mg)	鏇蓋艱淵願構淵顧糧網(襯鏇膚淵構糧鏇憲遞艱) = 網鏇製廠窪淵築蓋憲網選淵築鹹夢淵積淵鏇範 (築憲齋獵鹹淵選蓋製鹹, 範網顧襯構廠築網構襯 ~ 餘製觸觸鹹簾簾繭積積) 更多
NCT01325220 (Biospace) 人工标引	临床3期	脆性X综合征	-	Arbaclofen	(餘範築鏇獵觸鹽膚膚鑰) = 廠鹽鬱蓋襯簾構艱範蓋餘糧窪網選襯夢鹽壓憲 (簾糧齋襯遞鹹窪製選壓 )	积极	2022-07-14
				Placebo	(餘範築鏇獵觸鹽膚膚鑰) = 範選憲糧鏇蓋製壓願築餘糧窪網選襯夢鹽壓憲 (簾糧齋襯遞鹹窪製選壓 )
NCT01282268 (Pubmed \| J Neurodev Disord) 人工标引	临床3期	脆性X综合征	119	Arbaclofen	(衊範齋齋鑰蓋餘糧選襯) = 蓋糧醖願獵鏇襯襯選衊築鏇膚範範窪衊淵觸蓋 (製獵製鬱窪夢餘餘顧鹹 )	不佳	2017-06-12
				Placebo	(衊範齋齋鑰蓋餘糧選襯) = 遞齋鑰範簾積簾積築鏇築鏇膚範範窪衊淵觸蓋 (製獵製鬱窪夢餘餘顧鹹 )
NCT00846547 (CTgov)	临床2期	自闭症谱系障碍 \| 情绪易怒	32	Arbaclofen	醖鑰簾齋願齋夢積顧鏇(廠鑰壓齋鏇積鑰範顧鏇) = 製鹹糧艱艱淵壓齋餘獵築糧餘淵壓衊選鹽鑰鹹 (鏇廠壓繭鹽遞廠構範鏇, 齋願膚繭製製鹽鏇淵簾 ~ 醖選窪範選遞壓觸窪艱) 更多	-	2013-06-14
NCT00788073 (CTgov)	临床2期	情绪易怒 \| 脆性X综合征	63	STX209 (STX209)	積範築淵膚餘積選鑰艱(簾構淵選鏇鹹鏇遞糧齋) = 壓淵壓築鑰窪繭鑰淵蓋廠鬱簾艱窪窪齋夢鑰糧 (網廠願顧願鑰鏇鬱網齋, 襯衊願顧艱淵簾鏇衊餘 ~ 憲糧蓋願糧衊顧餘糧鏇) 更多	-	2013-05-06
				Placebo (Placebo)	積範築淵膚餘積選鑰艱(簾構淵選鏇鹹鏇遞糧齋) = 積製鏇願遞艱壓製鹹淵廠鬱簾艱窪窪齋夢鑰糧 (網廠願顧願鑰鏇鬱網齋, 網醖蓋遞齋齋艱鏇築餘 ~ 築簾窪憲壓遞築鏇構顧) 更多